Letter | Published:

Targeting nuclear RNA for in vivo correction of myotonic dystrophy

Nature volume 488, pages 111115 (02 August 2012) | Download Citation


Antisense oligonucleotides (ASOs) hold promise for gene-specific knockdown in diseases that involve RNA or protein gain-of-function effects. In the hereditary degenerative disease myotonic dystrophy type 1 (DM1), transcripts from the mutant allele contain an expanded CUG repeat1,2,3 and are retained in the nucleus4,5. The mutant RNA exerts a toxic gain-of-function effect6, making it an appropriate target for therapeutic ASOs. However, despite improvements in ASO chemistry and design, systemic use of ASOs is limited because uptake in many tissues, including skeletal and cardiac muscle, is not sufficient to silence target messenger RNAs7,8. Here we show that nuclear-retained transcripts containing expanded CUG (CUGexp) repeats are unusually sensitive to antisense silencing. In a transgenic mouse model of DM1, systemic administration of ASOs caused a rapid knockdown of CUGexp RNA in skeletal muscle, correcting the physiological, histopathologic and transcriptomic features of the disease. The effect was sustained for up to 1 year after treatment was discontinued. Systemically administered ASOs were also effective for muscle knockdown of Malat1, a long non-coding RNA (lncRNA) that is retained in the nucleus9. These results provide a general strategy to correct RNA gain-of-function effects and to modulate the expression of expanded repeats, lncRNAs and other transcripts with prolonged nuclear residence.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    et al. Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy. Nature 355, 545–546 (1992)

  2. 2.

    et al. Detection of an unstable fragment of DNA specific to individuals with myotonic dystrophy. Nature 355, 547–548 (1992)

  3. 3.

    et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 68, 799–808 (1992)

  4. 4.

    , , , & Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J. Cell Biol. 128, 995–1002 (1995)

  5. 5.

    , , , & Expansion of a CUG trinucleotide repeat in the 3′ untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts. Proc. Natl Acad. Sci. USA 94, 7388–7393 (1997)

  6. 6.

    et al. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 289, 1769–1773 (2000)

  7. 7.

    & RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50, 259–293 (2010)

  8. 8.

    et al. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab. Dispos. 31, 1419–1428 (2003)

  9. 9.

    , & 3′ end processing of a long nuclear-retained noncoding RNA yields a tRNA-like cytoplasmic RNA. Cell 135, 919–932 (2008)

  10. 10.

    , , , & Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 28, 582–592 (2000)

  11. 11.

    et al. Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J. Biol. Chem. 278, 7108–7118 (2003)

  12. 12.

    et al. Regulating gene expression through RNA nuclear retention. Cell 123, 249–263 (2005)

  13. 13.

    et al. Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J. Biol. Chem. 279, 17181–17189 (2004)

  14. 14.

    et al. An upstream open reading frame and the context of the two AUG codons affect the abundance of mitochondrial and nuclear RNase H1. Mol. Cell. Biol. 30, 5123–5134 (2010)

  15. 15.

    et al. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum. Mol. Genet. 15, 2087–2097 (2006)

  16. 16.

    et al. Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy. Hum. Mol. Genet. 18, 1471–1481 (2009)

  17. 17.

    et al. A muscleblind knockout model for myotonic dystrophy. Science 302, 1978–1980 (2003)

  18. 18.

    et al. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 325, 336–339 (2009)

  19. 19.

    , , , & Translation of stable hepadnaviral mRNA cleavage fragments induced by the action of phosphorothioate-modified antisense oligodeoxynucleotides. Nucleic Acids Res. 33, 114–125 (2005)

  20. 20.

    & CUG repeats present in myotonin kinase RNA form metastable “slippery” hairpins. J. Biol. Chem. 272, 31079–31085 (1997)

  21. 21.

    et al. Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J. 19, 4439–4448 (2000)

  22. 22.

    et al. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol. Cell 10, 35–44 (2002)

  23. 23.

    et al. Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nature Struct. Mol. Biol. 17, 187–193 (2010)

  24. 24.

    et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nature Med. 12, 175–177 (2006)

  25. 25.

    & Rapid assembly and disassembly of complementary DNA strands through an equilibrium intermediate state mediated by A1 hnRNP protein. J. Biol. Chem. 267, 13815–13818 (1992)

  26. 26.

    & Roles of trinucleotide-repeat RNA in neurological disease and degeneration. Trends Neurosci. 33, 292–298 (2010)

  27. 27.

    et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245–256 (2011)

  28. 28.

    et al. Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc. Natl Acad. Sci. USA 106, 13915–13920 (2009)

  29. 29.

    , & RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1. Proc. Natl Acad. Sci. USA 109, 4221–4226 (2012)

  30. 30.

    & Long noncoding RNAs and human disease. Trends Cell Biol. 21, 354–361 (2011)

  31. 31.

    , , , & Solid phase synthesis of phosphorothioate oligonucleotides utilizing diethyldithiocarbonate disulfide (DDD) as an efficient sulfur transfer reagent. Nucleosides Nucleotides Nucleic Acids 22, 461–468 (2003)

  32. 32.

    et al. Transgenic mice carrying large human genomic sequences with expanded CTG repeat mimic closely the DM CTG repeat intergenerational and somatic instability. Hum. Mol. Genet. 9, 1185–1194 (2000)

  33. 33.

    , & Stabilization of expanded (CTG)*(CAG) repeats by antisense oligonucleotides. Mol. Ther. 19, 2222–2227 (2011)

  34. 34.

    et al. Mice transgenic for the human myotonic dystrophy region with expanded CTG repeats display muscular and brain abnormalities. Hum. Mol. Genet. 10, 2717–2726 (2001)

  35. 35.

    et al. CTG trinucleotide repeat “big jumps”: large expansions, small mice. PLoS Genet. 3, e52 (2007)

  36. 36.

    , , , & Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J. Clin. Invest. 117, 3952–3957 (2007)

  37. 37.

    et al. Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res. 39, 4795–4807 (2011)

  38. 38.

    & A language for data analysis and graphics. J. Comput. Graph. Stat. 5, 299–314 (1996)

  39. 39.

    , & Principal components analysis to summarize microarray experiments: application to sporulation time series. Pac. Symp. Biocomput. 2000, 455–466 (2000)

  40. 40.

    What is principal component analysis? Nature Biotechnol. 26, 303–304 (2008)

  41. 41.

    , , , & Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse. Neuromuscul. Disord. 14, 675–682 (2004)

  42. 42.

    , , & Quantitation of phosphorothioate oligonucleotides in human plasma. Anal. Biochem. 235, 36–43 (1996)

  43. 43.

    , & A nonradioisotope biomedical assay for intact oligonucleotide and its chain-shortened metabolites used for determination of exposure and elimination half-life of antisense drugs in tissue. Anal. Biochem. 274, 241–248 (1999)

Download references


The work was carried out at the Wellstone Muscular Dystrophy Cooperative Research Center and Center for RNA Biology at the University of Rochester, with support from the US National Institutes of Health (NIH) (grants AR049077, U54NS48843, AR/NS48143, K08NS064293 and U01NS072323), the Saunders Family Neuromuscular Research Fund, Run America and a fellowship (to M.N.) from the Muscular Dystrophy Association and Uehara Memorial Foundation. The authors thank G. Gourdon for providing DM328XL mice, M. Sabripour for assistance with principal components analysis and L. Richardson and S. Leistman for technical assistance.

Author information


  1. Department of Neurology, University of Rochester, 601 Elmwood Avenue, Rochester, New York, 14642, USA

    • Thurman M. Wheeler
    • , Masayuki Nakamori
    •  & Charles A. Thornton
  2. Center for Neural Development and Disease, University of Rochester, 601 Elmwood Avenue, Rochester, New York, 14642, USA

    • Thurman M. Wheeler
    • , Masayuki Nakamori
    •  & Charles A. Thornton
  3. Genzyme Corporation, 49 New York Avenue, Framingham, Massachusetts 01701, USA

    • Andrew J. Leger
    • , Seng H. Cheng
    •  & Bruce M. Wentworth
  4. Isis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, California 92010, USA

    • Sanjay K. Pandey
    • , A. Robert MacLeod
    •  & C. Frank Bennett


  1. Search for Thurman M. Wheeler in:

  2. Search for Andrew J. Leger in:

  3. Search for Sanjay K. Pandey in:

  4. Search for A. Robert MacLeod in:

  5. Search for Masayuki Nakamori in:

  6. Search for Seng H. Cheng in:

  7. Search for Bruce M. Wentworth in:

  8. Search for C. Frank Bennett in:

  9. Search for Charles A. Thornton in:


Author Contributions T.M.W., A.J.L, S.K.P., A.R.M., M.N., S.H.C., B.M.W., C.F.B. and C.A.T. participated in the planning, design and interpretation of experiments. T.M.W., A.J.L., S.K.P., A.R.M and M.N. carried out experiments. T.M.W. and C.A.T. wrote the manuscript.

Competing interests

S.K.P., A.R.M. and C.F.B. are employees of Isis Pharmaceuticals, which develops antisense drugs. A.J.L., S.H.C. and B.M.W. are employees of Genzyme Corporation, which develops biological therapeutics. C.A.T. and T.M.W. received research support from Isis Pharmaceuticals. Isis Pharmaceuticals has applied for patents related to this work.

Corresponding author

Correspondence to Charles A. Thornton.

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    This file contains Supplementary Figures 1-18, Supplementary Tables 1-3 and Supplementary References.

About this article

Publication history






Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.